Acute Promyelocytic Leukemia Clinical Trial
Official title:
Phase II Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
The purpose of this study is to determine whether NRX 195183 is effective in the treatment of relapsed or refractory Acute Promyelocytic Leukemia
A common current therapeutic approach to APL uses oral ATRA and chemotherapy in induction and consolidation. This approach has significantly improved survival in newly diagnosed APL patients. However, approximately 30% of patients relapse. Recently, an approach involving the combination of oral ATRA and arsenic trioxide has been tested. The prognosis for relapsed patients is very poor. This study seeks to investigate NRX 195183 monotherapy in patients who have failed or are resistant to or are intolerant of any prior therapy. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00520208 -
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
|
Phase 2 | |
| Suspended |
NCT04996030 -
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT02899169 -
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
|
Phase 3 | |
| Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 | |
| Recruiting |
NCT04793919 -
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT02938858 -
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
|
N/A | |
| Recruiting |
NCT02991066 -
Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
|
||
| Terminated |
NCT00985530 -
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
|
Phase 1 | |
| Withdrawn |
NCT00670150 -
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT01064570 -
AIDA 2000 Guidelines
|
Phase 2 | |
| Completed |
NCT01472107 -
Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
|
||
| Active, not recruiting |
NCT03096496 -
Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
|
||
| Completed |
NCT00465933 -
Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)
|
Phase 4 | |
| Active, not recruiting |
NCT02688140 -
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
|
Phase 3 | |
| Active, not recruiting |
NCT01987297 -
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
|
Phase 4 | |
| Terminated |
NCT00907582 -
ASCT for Relapsed APL After Molecular Remission
|
Phase 2 | |
| Recruiting |
NCT00517712 -
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
|
Phase 2/Phase 3 | |
| Completed |
NCT01902329 -
A Safety Study of SGN-CD33A in AML Patients
|
Phase 1 | |
| Completed |
NCT01404949 -
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
|
Phase 2 | |
| Completed |
NCT00504764 -
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
|
Phase 4 |